title: Intraocular inflammation after intravitreal ranibizumab injections.
authors.forename: Sascha
authors.initials: S
authors.lastname: Fauser
authors.forename: Sabine
authors.initials: S
authors.lastname: Schroeder
authors.forename: Albert
authors.initials: A
authors.lastname: Caramoy
authors.forename: Bernd
authors.initials: B
authors.lastname: Kirchhof
authors.forename: Alexandra
authors.initials: A
authors.lastname: Lappas
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D000867:Anterior Chamber / Q000473:pathology; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D002442:Ceftazidime / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D009877:Endophthalmitis / Q000139:chemically induced* / Q000188:drug therapy; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D058449:Intravitreal Injections; D008268:Macular Degeneration / Q000188:drug therapy; D000069579:Ranibizumab; D019233:Retreatment; D014640:Vancomycin / Q000627:therapeutic use; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000187:drug effects; D014822:Vitreous Body / Q000473:pathology
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D005938:Glucocorticoids; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D014640:Vancomycin; D002442:Ceftazidime; D000069579:Ranibizumab